Gilead to Buy Kite for Promising Cancer Therapies in $12 Billion Deal Gilead to Buy Kite for Promising Cancer Therapies in $12 Billion Deal

Gilead Sciences Inc agreed to buy Kite Pharma Inc in a nearly $12 billion deal on Monday, as it looks to replace flagging sales from hepatitis C drugs with an emerging and expensive class of cancer immunotherapies that are expected to generate billions of dollars in revenue.Reuters Health Information
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Related Links:

Drug price regulator NPPA has fixed the ceiling price for 92 drug formulations, including those used for treatment of cancer, hepatitis C, migraine and diabetes among others.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
Advanced liver disease and related cancers diagnoses stable Related items fromOnMedica Electronic ‘pill’ may revolutionise gut diagnoses England aims to be first in the world to eliminate hepatitis C Public health doctors encourage hepatitis C testing Alcohol consumption in late teens can predict risk of liver problems later
Source: OnMedica Latest News - Category: UK Health Source Type: news
New Public Health England data shows a decrease in deaths from hepatitis C but diagnoses of advanced liver disease and related cancers remain stable.
Source: NHS Networks - Category: UK Health Source Type: news
We describe 2 patients with leprosy that developed during new treatments for hepatitis C and prostate cancer.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research
Optimal care for hepatitis virus –related hepatocellular carcinoma (HCC) would include eradication of tumor and elimination of hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Accomplishing these goals could prevent deaths from cancer or cirrhosis and reduce the likelihood of viral transmission. Tremendous progress h as recently been achieved for tumor and antiviral therapies. Long-term survival from cancer was previously a rarity. Now, partial hepatectomy, liver transplant, or tumor ablation provide 5-year survival rates of 45% to 80%. Direct-acting antivirals (DAA) can now prevent cirrhosis in patients...
Source: JAMA Surgery - Category: Sports Medicine Source Type: research
CONCLUSIONS: Aberrant β-catenin expression was seen in a substantial proportion of our HCC cases. β-catenin-positive HCC was associated with normal AFP levels, unicentric tumors, well-differentiated histology, and an unfavorable outcome.
Source: Indian Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
Liver International, EarlyView.
Source: Liver International - Category: Gastroenterology Authors: Source Type: research
δ-Tocotrienol is a naturally occurring proteasome inhibitor, which has the capacity to inhibit proliferation and induce apoptosis in several cancer cells obtained from several organs of humans, and other cance...
Source: Lipids in Health and Disease - Category: Lipidology Authors: Tags: Research Source Type: research
This study was conducted on a total number of 59patients. These were subdivided into 25patients of hepatocellular carcinoma and 34 patients of chronic liver diseases (CLDs) with cirrhosis. All studied 59patients were associated with HCV infection. All patients were examined immunohistochemically to demonstrate the expression of MyeloperoxidaseResultsConcerning the expression of Myeloperoxidase in HCC and cirrhoticpatients; the study revealed that more MPO expression was found in HCC cases when compared with cirrhoticpatients (P –value
Source: Meta Gene - Category: Genetics & Stem Cells Source Type: research
An estimated 150 million people have chronic hepatitis C infection (HCV) [1], 3.5 million of whom live in the United States [2]. Half are thought to be unaware of their status since many experience no adverse symptoms of infection until late in progression [3], but 20% will develop cirrhosis, 10% end-stage liver disease or cancer, and approximately 3% will require a liver transplant or die [4].
Source: Patient Education and Counseling - Category: International Medicine & Public Health Authors: Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | Hematology | Hepatitis | Hepatitis C | Immunotherapy | Pharmaceuticals